



12th Annual
Nantz National Alzheimer Center Symposium

Dementia With Lewy Bodies

Feb. 17, 2023

Program Director: Jon B. Toledo, MD, PhD

Program Co-Director: Joseph C. Masdeu, MD, PhD

HOUSTON
Methodist[®]
NEUROLOGICAL INSTITUTE



AGENDA

TIME	PRESENTATION	SPEAKER
7:30 AM	Registration and Breakfast	
8:30 AM	Welcome	Stanley H. Appel, MD
8:35 AM	Nantz Symposium Welcome	Jim Nantz, III
8:40 AM	Nantz Symposium Overview	Joseph C. Masdeu, MD, PhD
8:45 AM	Clinical Aspects of DLB and the Evolution of its Clinical Criteria	John-Paul Taylor, MD
9:25 AM	Q & A Discussion	
9:35 AM	DLB Neuropathology and Coincident Co-Pathologies	Jon B. Toledo, MD, PhD
10:15 AM	Q & A Discussion	
10:25 AM	BREAK	
10:35 AM	Genetics of DLB	Sonja W. Scholz, MD, PhD
11:15 AM	Q & A Discussion	
11:25 AM	Imaging Biomarkers in DLB	Kejal Kantarci, MD
12:05 PM	Q & A Discussion	
12:20 PM	LUNCH	
1:20 PM	Biofluid Biomarkers in DLB	Lynn M. Bekris, MS, PhD
2:00 PM	Q & A Discussion	
2:10 PM	Clinical Progression in DLB and Effects on Patients and Caregivers	Melissa J. Armstrong, MD
2:50 PM	Q & A Discussion	
3:00 PM	BREAK	
3:10 PM	Challenges and Opportunities in DLB Clinical Trials	James B. Leverenz, MD
3:50 PM	Q & A Discussion	
4:00 PM	Adjournment	

Click the link of the presentation to view the slides (PDF)*.

Slides are posted as they become available. Some slides may not be posted.

Refresh this link to check for updates.

Are the links not showing? We suggest trying another browser or downloading this pdf and open with a pdf viewer.

PROGRAM DIRECTORS

Jon B. Toledo, MD, PhD – PROGRAM DIRECTOR

Assistant Professor, Houston Methodist Stanley H. Appel Department of Neurology
Research Director, Nantz National Alzheimer Center

Joseph C. Masdeu MD, PhD – PROGRAM CO-DIRECTOR

Director, Nantz National Alzheimer Center
Houston Methodist Stanley H. Appel Department of Neurology

GUEST FACULTY

Melissa J. Armstrong, MD, MSc, FAAN

Associate Professor, Department of Neurology
Director, Mangurian Clinical-Research Headquarters for Lewy Body Dementia
Norman Fixel Institute for Neurological Diseases
Gainesville, Florida

Lynn M. Bekris, MS, PhD

Associate Professor of Molecular Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, Ohio

Kejal Kantarci, MD

Professor of Radiology
Neuroradiology Division, Department of Radiology
Mayo Clinic Rochester
Rochester, Minnesota

James B. Leverenz, MD

Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Cleveland, Ohio

Sonja W. Scholz, MD, PhD

Lasker Clinical Research Scholar, Neurodegenerative Diseases Research Unit
National Institute of Neurological Disorders and Stroke
Bethesda, Maryland

John-Paul Taylor, MD

Professor of Translational Dementia Research, Institute of Translational and Clinical Research
Newcastle University
Honorary Consultant in Old Age Psychiatry with the Cumbria, Northumberland, Tyne and Wear (NTW) NHS Trust
United Kingdom

HOUSTON METHODIST FACULTY

Stanley H. Appel, MD

Director, Ann Kimball & John W. Johnson Center for Cellular Therapeutics
Houston Methodist Stanley H. Appel Department of Neurology

PROGRAM OVERVIEW

The Nantz National Alzheimer Center symposium will examine the current knowledge regarding dementia with Lewy bodies (DLB). DLB shares the same defining pathology as Parkinson's (Lewy body pathology) but is associated with a faster progression. DLB is the second most common neurodegenerative cause of dementia after Alzheimer's disease. Despite its prevalence, DLB is frequently not recognized and has been studied to a lesser extent than Parkinson's disease and Alzheimer's disease. Our program will cover multiple aspects of DLB. We will review the evolution and clinical features of dementia with Lewy bodies. A review of the differences in the pathology and comorbidities present in DLB will follow this presentation. The symposium will continue with a description of the genetic landscape in DLB and its relation to Alzheimer's disease and Parkinson's disease. Moving to diagnosis and prognosis, the subsequent two presentations will describe imaging, cerebrospinal fluid, and blood biomarker advances in this condition. The last two sections will review the clinical progression and the impact on caregivers, ending with an overview and challenges for clinical trial design in DLB.

TARGET AUDIENCE

Physicians, scientists with an interest in neurobiology, neuropsychologists, speech pathologists, physician assistants, nurse practitioners, nurses, physical therapists, occupational therapists, social workers, residents and fellows will benefit from this course.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, the participant should be able to:

- Recognize the clinical signs and symptoms that define DLB
- Discuss the co-pathologies that are frequently present in DLB
- Identify the genetic correlates of DLB
- Identify the different clinical and research biomarkers and their differences
- Describe and recognize the impact of the progressive symptoms on caregivers
- Discuss the current and future landscape of clinical trials in DLB

NURSING OUTCOMES STATEMENT

Nurses should have an understanding of the neurobiology and pathophysiology affecting disorders their patients may be experiencing in order to better understand the development of new effective treatments. Nurses attending this course will be able to provide high quality, evidence-based care to patients with dementia with Lewy bodies and will be prepared to facilitate implementation of new therapies by anticipating care needs and providing accurate patient and family education and anticipatory guidance.

EDUCATIONAL METHODS

Didactic Lectures, Panel Discussions, and Question and Answer Sessions

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

Physicians

Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 6.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Houston Methodist will award 6.08 nursing continuing professional development contact hours for this activity. Participants must attend the activity in its entirety, and complete the corresponding items on the evaluation tool.

ASET Credit

The 12th Annual Nantz National Alzheimer Center Symposium: Dementia with Lewy Bodies, has been approved for 6 ASET CEU's.

Occupational Therapists

This activity has been approved for 5.75 hours of OT Education by The Texas Board of Occupational Therapy Examiners. The 12th Annual Nantz National Alzheimer Center Symposium: Dementia with Lewy Bodies is a TOTA Approved Course from February 17, 2023, to February 17, 2024-- Course #327-32.

Physical Therapists/Physical Therapist Assistants

This activity has been approved by the Texas Board of Physical Therapy Examiners for 5.75 CCUs for PTs and PTAs.

Social Workers

Houston Methodist designates this activity for 5.6 CEUs for social work. This offering complies with section 781.509 of the rules of The Texas State Board of Social Work Examiners www.bhec.texas.gov

HOW TO RECEIVE YOUR CERTIFICATE

Physicians/Occupational Therapists/Physical Therapists/Physical Therapist Assistants

An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

Nurses

To be awarded up to 6.08 contact hours for this continuing education activity, the participant must:

- Be sure to check in and complete the sign in process
- Attend each session in its entirety (Contact hours are awarded only for full day attendance)
- Complete the evaluation tool. An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

ASET

To be awarded 6 contact hours for this continuing education activity, the participant must complete their evaluation and enter in their ASET ID # on the evaluation tool. This information will be sent directly to ASET and recorded as CEU credit.

Social Workers

To be awarded up to 5.6 contact hours for this continuing education activity, the participant must:

- Be sure to check in and complete the sign in process.
- Attend each session in its entirety (Contact hours are awarded only for full day attendance)
- Complete the evaluation tool. An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be emailed a link to print/download your certificate in PDF format within one week of completing your evaluation.

DISCLAIMER AND DISCLOSURES

Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC), Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.

Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

Name	Role	Relevant Financial Relationship(s)
James B. Leverenz, MD	Speaker	Grant Support for Component of an NIH/NINDS Funded U01 Project (U01NS100610): GE Healthcare
Joseph C. Masdeu MD, PhD	Planning Committee Member	Royalties: Elsevier, Wolters Kluwer Health Speaker; Consultant: Biogen Consultant: Coxa Therapeutics, Lilly USA
Sonja W. Scholz, MD, PhD	Speaker	Researcher: Cerevel Therapeutics
John-Paul Taylor, MD	Speaker	Speaker: GE Healthcare Speaker: Bial (<i>Relationship Has Ended</i>) Consultant; Researcher: Sosei-Heptares Consultant: Kirin-Kyowa (<i>Relationship Has Ended</i>)

All the relevant financial relationships listed for these individuals have been mitigated.

All others in control of content for this activity have no relevant financial relationships with ineligible companies to disclose.